《滬深兩市》上證深成半日跌0.5%-0.8% 創板跌2.3% 醫藥、醫美股受壓
人行今日開展100億元7天期逆回購操作，中標利率維持2.2%，今日有300億元逆回購到期。人幣中間價上調82點。上證深成個別發展後曾雙雙向上，其後資金流出下走勢轉弱，其中創業板跌逾2%。
上證低見3,502，半日反覆跌18點或0.5%，收報3,515點；深成跌121點或0.8%，收報14,597點；滬深300指數跌30點或0.6%，報5,055點；創業板指數跌77點或2.3%，收報3,274點，成交1,735億元。滬深兩市成交分別爲3,176億元及4,056億元。
中資金融股表現向好，工行(601398.SH)、建行(601939.SH)分別升0.6%、0.8%。
OPEC+暫停石油增產磋商，油價向好，中國石油(601857.SH)、中石化(600028.SH)分別升1%、0.9%。
鋰電池股持續上揚，西藏礦業(000762.SZ)漲停。國軒高科(002074.SZ)、融捷股份(002192.SZ)、雅化集團(002497.SZ)分別升1.2%、3.6%、4.2%。
光伏股走低，中來股份(300393.SZ)挫10.6%。金辰股份(603396.SH)、固德威(688390.SH)、拓日新能(002218.SZ)跌4.2%-7.9%。
醫藥、醫美股持續下挫，愛博醫療(688050.SH)、泰格醫藥(300347.SZ)、美迪西(688202.SH)分別急挫16%、14.2%、11.6%。復星醫藥(600196.SH)、通策醫療(600763.SH)跌停。愛爾眼科(300015.SZ)、康龍化成(300759.SZ)、藥明康德(603259.SH)挫7.2%-9.7%。奧園美谷(000615.SZ)跌停。金髮拉比(002762.SZ)、國際醫學(000516.SZ)、朗姿股份(002612.SZ)跌4.9%-7.2%。中藥股片仔(黃)(600436.SH)、同仁堂(600085.SH)、信邦製藥(002390.SZ)跌6.5%-8.6%。
食品飲料股持續走弱，安井食品(603345.SH)、良品鋪子(603719.SH)、百龍創園(605016.SH)、安琪酵母(600298.SH)、海天味業(603288.SH)跌1.7%-8.3%。
中國中免(601888.SH)上半年淨利潤按年增逾4.8倍，股價倒跌1.3%。
蘇寧易購(002024.SZ)復牌漲停，擬轉讓16.96%股權，江蘇國資聯手阿裏小米入局，深國資退出；轉讓後公司將無實控人。公司預計上半年虧損25億元-32億元。
萬東醫療(600055.SH)漲停。公司擬定增募資不超過20.83億元，用於MRI產品、CT產品、DSA產品、DR及DRF產品等研發及產業化項目，控股股東美的集團將以現金方式全部認購。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
